Literature DB >> 9477957

Dislodgment and accelerated degradation of Ras.

R Haklai1, M G Weisz, G Elad, A Paz, D Marciano, Y Egozi, G Ben-Baruch, Y Kloog.   

Abstract

Membrane anchorage of Ras oncoproteins, required for transforming activity, depends on their carboxy-terminal farnesylcysteine. We previously showed that S-trans,trans-farnesylthiosalicylic acid (FTS), a synthetic farnesylcysteine mimetic, inhibits growth of ErbB2- and Ras-transformed cells, but not of v-Raf-transformed cells, suggesting that FTS interferes specifically with Ras functions. Here we demonstrate that FTS dislodges Ras from membranes of H-Ras-transformed (EJ) cells, facilitating its degradation and decreasing total cellular Ras. The dislodged Ras that was transiently present in the cytosol was degraded relatively rapidly, causing a decrease of up to 80% in total cellular Ras. The half-life of Ras was 10 +/- 4 h in FTS-treated EJ cells and 27 +/- 4 h in controls. The dislodgment of membrane Ras and decrease in total cellular Ras were dose-dependent: 50% of the effects occurred at 10-15 microM, comparable to concentrations (7-10 microM) required for 50% growth inhibition in EJ cells. Higher concentrations of FTS (25-50 microM) were required to dislodge Ras from Rat-1 cell membranes expressing normal Ras, suggesting some selectivity of FTS toward oncogenic Ras. Membrane localization of the prenylated G beta gamma of heterotrimeric G proteins was not affected by FTS in EJ cells. An FTS-related compound, N-acetyl-S-farnesyl-L-cysteine, which does not inhibit EJ cell growth, did not affect Ras. FTS did not inhibit growth of Rat-1 cells transformed by N-myristylated H-Ras and did not reduce the total amount of this Ras isoform. The results suggest that FTS affects docking of Ras in the cell membrane in a rather specific manner, rendering the protein susceptible to proteolytic degradation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477957     DOI: 10.1021/bi972032d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  58 in total

Review 1.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Authors:  Adrienne D Cox; Channing J Der; Mark R Philips
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

Review 2.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

Review 3.  Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.

Authors:  Richard J Santen; Robert X Song; Shigeru Masamura; Wei Yue; Ping Fan; Tetsuya Sogon; Shin-ichi Hayashi; Kei Nakachi; Hidtek Eguchi
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

4.  Separate cyclic AMP sensors for neuritogenesis, growth arrest, and survival of neuroendocrine cells.

Authors:  Andrew C Emery; Maribeth V Eiden; Lee E Eiden
Journal:  J Biol Chem       Date:  2014-02-24       Impact factor: 5.157

Review 5.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

6.  An increase in tolerogenic dendritic cell and natural regulatory T cell numbers during experimental autoimmune encephalomyelitis in Rras-/- mice results in attenuated disease.

Authors:  Avijit Ray; Sreemanti Basu; Nichole M Miller; Andrew M Chan; Bonnie N Dittel
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

7.  PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel.

Authors:  Xiaolan Zhang; Jianqin Lu; Yixian Huang; Wenchen Zhao; Yichao Chen; Jiang Li; Xiang Gao; Raman Venkataramanan; Ming Sun; Donna Beer Stolz; Lin Zhang; Song Li
Journal:  Bioconjug Chem       Date:  2013-03-01       Impact factor: 4.774

8.  K-ras 4A and 4B mRNA levels correlate with superoxide in lung adenocarcinoma cells, while at the protein level, only mutant K-ras 4A protein correlates with superoxide.

Authors:  Richard J Calvert; Meghana Gupta; Anna Maciag; Yih-Horng Shiao; Lucy M Anderson
Journal:  Lung Cancer       Date:  2013-03-06       Impact factor: 5.705

9.  Structure-function analysis of nucleolin and ErbB receptors interactions.

Authors:  Keren Farin; Ayelet Di Segni; Adam Mor; Ronit Pinkas-Kramarski
Journal:  PLoS One       Date:  2009-07-03       Impact factor: 3.240

10.  Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling.

Authors:  A B Hanker; N Mitin; R S Wilder; E P Henske; F Tamanoi; A D Cox; C J Der
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.